HLA-DR2, a marker for class I antigen sensitization.
After analysis of 423 hemodialysis patients in a transfusion program and 461 cadaver-donor renal transplants, we found that HLA-DR2 frequency was significantly higher in the responder (36%) than in the nonresponder patient group (19%), according to the percentage of PRA (panel reactive antibodies). Among DR2+ patients, the percentage of hypersensitized patients was twice that of DR2- patients. Graft survival curves in cadaver-donor renal transplants indicated a significantly lower survival when recipients were DR2+, even in recipient-donor pairs identical for class II antigens but mismatched for class I antigens. The prognostic probability of low response to transfusions by a stepwise logistic regression analysis showed the influence of sex and DR2 phenotype. By multivariant discriminant analysis, we found that the DR2 phenotype was one of the most influential transfusion sensitization risk factors. Our preliminary conclusion is that DR2 can be related to immune responsiveness to class I antigens.
Kreisler
J M
JM
Department of Immunology, Clinica Puerta de Hierro, Madrid, Spain.
Rementeria
M C
MC
de Pablo
R
R
Moreno
M E
ME
D000961:Antilymphocyte Serum / Q000032:analysis / Q000096:biosynthesis*; D002102:Cadaver; D005260:Female; D005787:Gene Frequency; D006085:Graft Survival; D006681:HLA-D Antigens / Q000032:analysis*; D006684:HLA-DR Antigens / Q000032:analysis* / Q000235:genetics / Q000276:immunology; D015802:HLA-DR2 Antigen; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D010641:Phenotype; D011379:Prognosis; D012307:Risk Factors; D012737:Sex Factors; D014019:Tissue Donors; D065227:Transfusion Reaction
D000961:Antilymphocyte Serum; D006681:HLA-D Antigens; D006684:HLA-DR Antigens; D015802:HLA-DR2 Antigen